A recorder is available during non-working hours. 2.4 T REATMENT ASSIGNMENT AND RANDOMIZATION /STRATIFICATION PROCEDURES Cohorts Number Name Description 1 Cohort 1 Patients with nonmetastatic castration sensitive prostate cancer Arms Letter Name Description A Standard dose enzalutamide aloneEnzalutamide alone administered at the standard dose (160 mg daily) B Enzalutamide with PSA- TRICOMStandard dose enzalutamide with concomitant vaccinia-PSA-TRICOM and then fowlpox-vaccine Stratifications Version Date: 12/5/17 Abbreviated Title : Enzalutamide in non-met CSPC 27Name Distinct Options Notes PSA doubling time less than 6 months Yes No Randomization and Arm Assignment After confirmation of eligibility at Central Registration Office (CRO ), patients in cohort 1 will be randomized on a 1:1 basis between arms A and B, stratifying for PSA doubling time using acomputerized randomization process. CRO staff will send a secured e-mail to Principal Investigator and research nurse with the Verification of Registration of th e patient and treatment arm patient is randomized.